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Background: Postoperative lymphedema in breast cancer survivors is a serious complication that develops 
from axillary lymph node dissection (ALND), chemotherapy, and radiation therapy. Axillary reverse mapping 
(ARM) was recently introduced to reduce lymphedema. This pilot study aimed to investigate the feasibility 
of preserving the ARM node using fluorescence imaging for patients at high risk of lymphedema.
Methods: We prospectively screened patients with breast cancer who had pathologic node-positive disease 
at diagnosis and were scheduled for neoadjuvant chemotherapy (NCT). The sentinel lymph node (SLN) was 
identified using blue dye and radioisotope, while the ARM node was traced using indocyanine green (ICG). 
In cases in which SLN was negative on the intraoperative frozen section examination, the ARM node and 
lymphatics were preserved.
Results: Of the 20 screened patients, six whose metastatic axillary lymph node (ALN) was converted 
to clinically node-negative disease after NCT were enrolled. No patients experienced recurrence at  
24 months postoperative. Four patients who had a preserved ARM node did not develop lymphedema. One 
patient whose ARM node was not preserved due to SLN identification failure did not develop postoperative 
lymphedema. One patient who underwent ALND without ARM node conservation because of metastatic 
SLN on frozen section examination developed postoperative lymphedema.
Conclusions: ARM is oncologically safe, decreases the incidence of postoperative lymphedema, and allows 
for the early detection of postoperative lymphedema in patients who underwent ALND. Ultimately, ARM 
may help improve the quality of life of patients with pathologic node-positive breast cancer.
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Introduction
Axillary lymph node (ALN) status is the most important 
prognostic factor for patients with breast cancer (1). Sentinel 
lymph node biopsy (SLNB) was developed to evaluate ALN 
metastasis and prevent complications following axillary 
lymph node dissection (ALND) (2). SLNB is the standard 
modality used to assess the ALN metastatic burden of 
patients with clinical node-negative breast cancer. SLNB is 
possible in patients with clinically node-negative disease at 
the time of surgery after neoadjuvant chemotherapy (NCT) 
and even in patients with cytologically proven node-positive 
disease before treatment (3-5).
The improved survival rate of patients with breast 
cancer has led to an increased quality of life. Lymphedema 
diminishes the quality of life of breast cancer survivors. 
Postoperative lymphedema develops from various factors 
and treatment modalities including ALND, radiation 
therapy, chemotherapy, postoperative infection, and higher 
body mass index (BMI) (6). Several methods to reduce 
lymphedema have been developed and evaluated. Among 
such procedures, axillary reverse mapping (ARM) has been 
evaluated in various studies (7-11). One study reported that 
postoperative ipsilateral lymphedema occurs due to lymph 
stasis resulting from impaired lymphatic drainage from the 
arm during axillary surgery (11). The ARM node is detected 
via mapping of the lymphatic drainage from the ipsilateral 
arm at the axillary area. The ARM technique is indicated 
to prevent or detect postoperative lymphedema at the early 
stage through preservation of the ARM node.
Several mapping techniques are available to identify 
the lymph node including blue dye and radioisotope. 
Several recent studies reported using the mapping method 
with indocyanine green (ICG) (12-14). ICG injected into 
the interstitial tissue is taken up by the lymphatics (15), 
and fluorescence imaging allows for visualization of 
the subcutaneous lymphatic pathway. ICG mapping is 
reportedly safe and useful and an alternative modality to 
blue dye or radioisotope mapping (16).
The risk of lymphedema markedly increases in 
patients who undergo ALND, radiation therapy, and 
chemotherapy. Thus, the clinical challenge is reducing 
the incidence of lymphedema or detecting it at an early 
stage, before the refractory phase, in patients at high risk 
of this complication. Therefore, we hypothesized that if 
histologically proven node-positive disease is converted to 
clinically node-negative disease at the time of surgery and 
the SLN is negative on the frozen section examination, 
complete ALND can be omitted. Moreover, preserving the 
ARM node reduces postoperative lymphedema, even in those 
who underwent ALND. This pilot study aimed to investigate 
the feasibility of preserving the ARM node using fluorescence 
imaging for patients at high risk of lymphedema.
Methods
Patient selection
We prospectively screened patients with clinical N1(f) breast 
cancer at diagnosis who underwent NCT between March 
and July 2017 at Severance Hospital (Seoul, South Korea). 
The clinical category of the primary tumor and regional 
lymph node was assessed according to the American Joint 
Committee on Cancer Staging Manual eighth edition (17). 
The exclusion criteria were stage IV or clinical T4 or 
clinical N2 or higher breast cancer at diagnosis. NCT 
regimens were chosen by the physician according to clinical 
stage, hormonal receptor status, and human epidermal 
growth factor receptor 2 (HER2) according to the American 
Society of Clinical Oncologists/College of American 
Pathologist guidelines (18). The molecular subtypes 
included luminal A-like, luminal B-like, HER2-positive, 
and triple-negative according to the European Society for 
Medical Oncology Clinical Practice guideline (19). The 
primary tumor response to NCT was evaluated according to 
the response criteria of the Japanese Breast Cancer Society (20). 
The ALN response to NCT was defined as disappearance of 
the metastatic lymph node on ultrasonography and magnetic 
resonance imaging after preoperative image studies. The breast 
cancer response to NCT was sequentially assessed using physical 
examination, mammography, ultrasonography, and magnetic 
resonance imaging. Finally, the patients with suspicious ALN 
findings, a palpable enlarged lymph node, loss of the fatty hilum, 
cortical thickening >3 mm, or markedly hypoechoic cortex after 
NCT were excluded.
Ethical statement
This study was approved by the Institutional Review Board 
of Severance Hospital, Yonsei University Health System 
(2018-2590-001). Written informed consent was obtained 
from all patients prior to study participation.
Mapping technique
The SLN was traced using radioisotopes and blue dye 
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(Figure 1). The ARM node was traced using ICG. We 
diluted 0.5 mCi 99mTc-Phytate (Korea Atomic Energy 
Research Institute, Daejeon, Korea) in 0.5 mL of saline 
and injected it into the areolar subcutaneous layer in the 
direction of the primary tumor at the Department of 
Nuclear Medicine immediately prior to the surgery. After 
the induction of general anesthesia, 0.8% indigo carmine 
dye (Carmine, Korea United Pharm Inc., Seoul, Korea) was 
injected at four points around the areola, and 0.5 mg/mL 
ICG (Allencare, Seoul, Korea) was diluted in 1 mL saline 
and injected into the ipsilateral medial aspect of the wrist 
and the second webspace of the hand. The SLN was defined 
as a hot, blue, and palpable node. Nodes >10% of the most 
radioactive node on a handheld gamma probe (Neoprobe 
Gamma Detection System, Neoprobe Corp., Dublin, OH, 
USA) were identified as hot nodes. Blue nodes and any 
lymph nodes at the end of a blue lymphatic channel were 
considered to be SLNs. Clinically suspicious palpable nodes 
in the surgical field were also resected as SLNs. ARM nodes 
were visualized under near-infrared fluorescence imaging 
with SPY Elite® (Novadaq Technologies, Inc., Bonita 
Springs, FL, USA).
Axillary surgery
All axillary surgeries were performed through separate 
axillary incisions. After dividing the clavipectoral fascia, we 
traced the ARM node and lymphatics from the ipsilateral 
arm using a fluorescence camera. These procedures were 
repeated during axillary surgery. First, each SLN was 
excised in the axillary cavity based on the hot, blue, palpable 
node. Each SLN was then sent for frozen-section analysis. 
If an SLN was negative, we performed ALND with 
preservation of the ARM node and lymphatics. Meanwhile, 
if an SLN was positive or not traced, we performed ALND 
without preserving the ARM node and lymphatics. ALND 
was performed according to standard criteria. Postoperative 
clinical follow-up was scheduled at regular 6-month 
intervals or performed whenever the patients had subjective 
abnormal symptoms including arm swelling, heaviness, 
firmness, tightness, and limited arm movement.
Lymphedema










Figure 1 Mapping technique of SLN and ARM node. Manual for ALN surgery in select cases. (A) Anatomy of breast and ALN; (B) 
mapping technique of SLN and ARM node; (C) SLN-ARM node non-crossover and node-negative disease confirmed via frozen section 
examination; (D) SLN-ARM node crossover or node-positive disease confirmed via frozen-section examination; (E) SLN identification 
failure. SLN, sentinel lymph node; ARM, axillary reverse mapping; ALN, axillary lymph node.
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preoperative period and every 6 months. Patients who 
had subjective abnormal symptoms in the ipsilateral arm 
or abnormal findings on a self-check were instructed to 
visit the hospital for an arm circumference assessment. 
At the Department of Rehabilitation Medicine, a clinical 
lymphologist evaluated the arm status via physical 
examination and limb circumference measurement using 
a flexible non-stretch ruler. Portions of the hand (thumb, 
thena, hypothena, and superior metacarpal), wrist, and 
5-cm increments starting at the folding line at elbow flexion 
from the wrist to the axilla were measured. The criterion 
for diagnosis of lymphedema was a circumference ≥2 cm 
compared with that of the contralateral limb based on 
the International Society of Lymphology guideline (21). 
Patients with a circumferential difference <2 cm of the 
bilateral limbs or no abnormal finding on expert physical 
examination underwent sequential circumferential arm 
measurements and lymphoscintigraphy. Abnormal findings 
on lymphoscintigraphy included dermal backflow, collateral 
lymphatic vessels, and decreased lymphatic uptake.
Results
Patient characteristics
Of the 20 patients who were screened, six were included 
in our pilot study. The detailed patient characteristics are 
shown in Table 1. The median age was 57 (range, 52–67) years 
at the time of treatment, and the mean follow-up duration 
was 24 months. All patients had invasive ductal carcinoma. 
The median breast tumor size was 2.1 (range, 1.4–3.2) cm 
on ultrasonography at the time of diagnosis. Three patients 
had HER2-positive disease, while the other three had 
triple-negative breast cancer. All patients who underwent 
total mastectomy also underwent radiation therapy at the 
chest wall, level III lymph node, internal mammary lymph 
node, and supraclavicular lymph. Meanwhile, those who 
underwent breast-conserving mastectomy underwent 
radiation therapy of the entire breast, tumor bed, level 
III lymph node, internal mammary lymph node, and 
supraclavicular lymph node. Three patients with both a 
primary tumor and node positivity achieved a pathologic 
complete response (pCR) to NCT.
ALN
An SLN (hot and/or blue) was detected in five patients. The 
identification rate of SLN using the dual method was 83.3% 
(5/6). The median number of retrieved SLN and total ALN 
(SLN + non-SLN + ARM node; only cases in which the 
ARM node was not preserved) were 1.5 (range, 0–2) and 6.5 
(range, 4–11), respectively (Table 2). Only one patient was 
confirmed to have a metastasis in the ALN including the 
SLN and non-sentinel ALN. The metastatic foci of ALN 
was measured to be 3 and 4 mm on permanent section by a 
specialist in breast pathology. Furthermore, this metastatic 
SLN connected with the ARM node in the axillary cavity 
(Figure 2). The nodal pCR rate to NCT was 83.3%. In cases 
of SLN mapping failure, the SLN could not be traced using 
the dual method; however, the lymphatic pathway from the 
ipsilateral arm was visualized on fluorescence imaging. This 
patient underwent ALND without preservation of the ARM 
node. Two patients did not achieve ARM node preservation 
because the SLN was not identified and because of 
Table 1 Clinicopathologic characteristics of the patients
Patient no. Age BMI NCT Breast surgery ALN RTx. Pathologic TNM stage ER PR HER2
1 57 23.94 AC → wP + H TM (+) ypTisN0 (–) (–) 3
2 57 19.31 AC → wP + H BCS (+) ypT0N0 (–) (–) 3
3 35 21.03 TCHP BCS (+) ypT1bN1 (+) (+) 3
4 59 29.64 AC → wP BCS (+) ypT0N0 (–) (–) 0
5 67 27.34 AC → wP BCS (+) ypT1aN0 (–) (–) 0
6 52 21.09 AC → wP TM (+) ypT1aN0 (–) (–) 0
Hormone receptor status and HER2 gene expression were evaluated via core needle biopsy prior to the NCT. BMI, body mass 
index; NCT, neoadjuvant chemotherapy; ALN, axillary lymph node; RTx., radiation therapy; TNM, tumor, node, metastasis; ER, 
estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AC, anthracycline followed by 
cyclophosphamide; wP, weekly paclitaxel; H, trastuzumab; BCS, breast-conserving surgery; TM, total mastectomy; CHP, docetaxel/
carboplatin/trastuzumab/pertuzumab.
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SLN-ARM node crossover. No patient developed regional 
recurrence during the 24-month follow-up.
Lymphedema
Three patients had subjective symptoms in the ipsilateral 
arm. Of them, two underwent evaluations of the lymphatic 
pathway of the ipsilateral arm via lymphoscintigraphy 
because the arm circumference did not fulfi l l  the 
lymphedema criteria. No abnormal findings were noted 
on lymphoscintigraphy. One other patient was diagnosed 
with grade I lymphedema. She underwent ALND without 
preservation of the ARM node owing to SLN metastasis and 
SLN-ARM node crossover. Only one of the two patients 
















1 0/7 (Hot/blue/0/2) 0/5 (Flu/?/?) (–) (+) No abnormal findings (–)
2 0/6 (–/–/0/2) 0/4 (Flu/–/2) (–) (–) Not done (–)
3 2/10 (–/blue/1/2) 1/8 (Flu/1/1) (+) (–) Not done (+)
4 0/4 (Hot/blue/0/2) 0/2 (Flu/?/?) (–) (+) No abnormal findings (–)
5 0/6 (Hot/blue/0/1) 0/5 (Flu/?/?) (–) (+) Not done (–)
6 0/11 (Hot/blue/0/1) 0/10 (Flu/?/?) (–) (+) Not done (–)




Figure 2 Identification of ARM node and lymphatics from the ipsilateral arm using fluorescence imaging. (A) Intraoperative photo of SLN-
ARM node crossover; (B) fluorescence image of SLN-ARM node crossover; (C) identification of the ARM node and pathway during SLN 
resection; (D) preserving the ARM node and lymphatics during ALND. ARM, axillary reverse mapping; SLN, sentinel lymph node; ALND, 
axillary lymph node dissection.
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who underwent ALND without ARM node preservation 
developed lymphedema.
Discussion
In our pilot study, we evaluated the mapping technique 
for identifying the lymphatic channel from the ipsilateral 
arm via ICG injection and verified the technical feasibility 
of preserving the ARM node and lymphatics through 
near-infrared fluorescence imaging for patients who are 
candidates for ALND.
Patients with node-positive breast cancer at diagnosis 
receive more aggressive treatment than those with node-
negative disease. These treatments, including ALND, 
radiation therapy, and systemic chemotherapy, are associated 
with postoperative ipsilateral lymphedema. For oncologic 
safety, ALND is pursued in some patients who undergo 
immediate surgery after the pathologic confirmation of 
ALN metastasis. However, complete ALND can be skipped 
in some patients with clinical node-negative disease before 
surgery who underwent NCT following the diagnosis of 
node-positive disease during the pretreatment period (22).
A retrospective multicenter analysis compared the 
disease-free and overall survival between patients who 
underwent ALND based on the SLNB result and those 
who underwent complete ALND without SLNB after 
NCT (23). The SLNB-guided decision group had higher 
rates of axillary recurrence than the complete ALND group 
with marginal significance (hazard ratio, 2.33; P=0.061). 
The higher regional recurrence rate in the SLNB-
guided decision group might have been induced by the 
lower diagnostic performance of SLNB in previous NCT 
patients. Furthermore, several clinical trials reported the 
performance of SLNB for patients with confirmed node-
positive disease at diagnosis who underwent NCT (3-5). 
The overall false-negative rate of SLNB was 14.2% in the 
SENTinel NeoAdjuvant study, 12.6% in the American 
College of Surgeons Oncology Group Z1071 (Alliance) 
trial, and 13.3% in the Sentinel Node Biopsy Following 
Neoadjuvant Chemotherapy trial .  The diagnostic 
performance of SLNB was improved via tattooing or 
clipping before NCT in patients with confirmed positive 
ALN (24). If tattooing or clipping was not performed 
for positive ALN before NCT, the false-negative rate of 
SLNB exceeded 10%. Furthermore, long-term follow-
up results are needed to clarify the diagnostic performance 
and oncological safety of SLNB in these cases. To ensure 
superior diagnostic accuracy and oncologic safety, aggressive 
axillary surgery should be considered until the benefits of 
SLNB for these patients is clarified.
Several studies reported that the ARM technique has 
some limitations (12,25,26) including the possibility of a 
decreased detection rate of SLN or ARM node if only one 
mapping material is used. Furthermore, the rate of ARM 
node identification differs between SLNB and ALND, which 
indicates that the ARM pathway is located on a deeper layer 
than the SLNB tract or that the transit times of the blue dye 
through the ARM lymphatics is not suitable for identifying 
ipsilateral arm lymphatics. Furthermore, in a previous NCT 
response study, the SLNB accuracy and pCR to NCT 
for cytologically proven node-positive disease with triple-
negative breast cancer were 97.1% and 58.8%, respectively, 
using only the radioisotope mapping method (27). 
If the diagnostic performance is enhanced via the dual 
mapping method including radioisotope and blue dye, 
ALND with ARM node preservation might be acceptable 
diagnostic modalities. However, it is possible that ARM 
node metastasis, ARM node crossover with SLN, and 
false negative result of SLNB frozen section examination 
occurred (8,10). Therefore, for oncologic safety, extended 
axillary surgery with ARM node preservation should be 
performed in selective patients with advanced nodal status at 
diagnosis. The eligibility criteria for this surgery are clinical 
node-negative disease after NCT, node-negative disease 
confirmed via intraoperative frozen section examination, 
and no connection between the SLN pathway and ARM 
pathway in the axillary cavity. Complete ALND or axillary 
radiotherapy should be considered for some patients with a 
false-negative SLNB result on a frozen section examination.
In conclusion, triple mapping techniques can help identify 
the SLN and ARM nodes and assess their correlation and 
metastatic burden. The ARM node-preserving technique 
might decrease the rate of postoperative lymphedema in 
patients at high risk of this complication. Appropriate 
prevention techniques, early diagnosis, and treatment are 
crucial to improve the quality of life of patients who develop 
post-treatment complications. Clinical trials designed to 
identify treatment modalities yielding lower complications 
while providing optimal effect are needed. Ultimately, the 
ARM technique may help improve the quality of life of 
patients with pathologic node-positive breast cancer.
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